Results 201 to 210 of about 330,850 (283)

Selective expansion of T-cell receptor engineered T cells with increased stem-like phenotypes using neoantigen stimulation. [PDF]

open access: yesJ Immunother Cancer
Kim SP   +15 more
europepmc   +1 more source

Mucosal‐Associated Invariant T Cells in Rheumatic Diseases

open access: yesArthritis &Rheumatology, EarlyView.
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek   +7 more
wiley   +1 more source

Lifelong evolution of autoreactive plasma cell numbers, affinity and anatomical location in arthritic K/BxN mice

open access: yesArthritis &Rheumatology, Accepted Article.
Objective The spontaneous K/BxN mouse model of rheumatoid arthritis has been used extensively to study chronic inflammation, contribution of immune cells, and the primordial role of autoreactive antibodies in disease initiation and severity. Only the ubiquitous enzyme glucose‐6‐phosphate isomerase (GPI) is the target of IgG autoantibodies secreted by ...
Thibault Vanhoucke   +8 more
wiley   +1 more source

Immunologic Profiling Suggests an Association Between Treg Cell Dysfunction and Pain in Knee Osteoarthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Pain is the hallmark symptom of osteoarthritis (OA), and its biologic drivers remain poorly understood. Although the role of innate immunity in OA has been extensively studied, the involvement of adaptive immunity, in particular Treg cells, is not well understood.
Marie Binvignat   +26 more
wiley   +1 more source

Sideways lipid presentation by the antigen-presenting molecule CD1c. [PDF]

open access: yesNat Commun
Cao TP   +17 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi   +12 more
wiley   +1 more source

Combined effect of increasing the post‐reformer temperature and adding red mud as a secondary catalyst in the thermocatalytic reforming of digestate

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract This work studies the combined effect of increasing the post‐reformer temperature and introducing red mud as a support catalyst in the thermocatalytic reforming (TCR®) of digestate. The TCR® method, developed by the Fraunhofer Institute for Environmental, Safety and Energy Technology UMSICHT (abbreviated as Fraunhofer UMSICHT), is an extension
Hillary Onyishi   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy